Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma
Background/Aim: This study investigated the predictive ability of intra-tumor enhancement on computed tomography (CT) for the outcomes of patients with pancreatic ductal adenocarcinoma (PDA). Methods: Multi-phase, contrast-enhanced CT (including unenhanced, pancreatic parenchymal phase (PPP) and por...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/10/2476 |
| _version_ | 1797500971482349568 |
|---|---|
| author | Dong Woo Shin Jaewon Park Jong-Chan Lee Jaihwan Kim Young Hoon Kim Jin-Hyeok Hwang |
| author_facet | Dong Woo Shin Jaewon Park Jong-Chan Lee Jaihwan Kim Young Hoon Kim Jin-Hyeok Hwang |
| author_sort | Dong Woo Shin |
| collection | DOAJ |
| description | Background/Aim: This study investigated the predictive ability of intra-tumor enhancement on computed tomography (CT) for the outcomes of patients with pancreatic ductal adenocarcinoma (PDA). Methods: Multi-phase, contrast-enhanced CT (including unenhanced, pancreatic parenchymal phase (PPP) and portal venous phase (PVP)) images of patients diagnosed with non-metastatic PDA were analyzed to investigate prognostic factors. Results: Two hundred ninety-eight patients with PDA (159 with resectable pancreatic cancer (RPC) and 139 with borderline resectable pancreatic cancer (BRPC)/locally advanced pancreatic cancer (LAPC)) were included. The attenuation values of PDA during the PPP (94.5 vs. 60.7 HU; <i>p</i> <0.001) and PVP (101.5 vs. 75.5 HU; <i>p</i> <0.001) were higher in patients with RPC than in those with BRPC/LAPC. Well-enhanced PDA during the PPP was associated with longer overall survival in the RPC group (27.9 vs. 15.4 months; <i>p</i> <0.001) and the BRPC/LAPC group (22.7 vs. 13.6 months; <i>p</i> = 0.024). Patients with BRPC/LAPC who underwent neoadjuvant treatment and had well-enhanced PDA during the PPP were more likely to undergo resection. Although tumor size was also an independent prognostic factor, it was not correlated with intra-tumoral enhancement during the PPP. Conclusions: Intra-tumoral contrast enhancement on CT is an independent prognostic factor in patients with non-metastatic PDA. |
| first_indexed | 2024-03-10T03:11:33Z |
| format | Article |
| id | doaj.art-62432f38db7741c39063a9628ab1e12d |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T03:11:33Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-62432f38db7741c39063a9628ab1e12d2023-11-23T10:23:44ZengMDPI AGCancers2072-66942022-05-011410247610.3390/cancers14102476Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal AdenocarcinomaDong Woo Shin0Jaewon Park1Jong-Chan Lee2Jaihwan Kim3Young Hoon Kim4Jin-Hyeok Hwang5Department of Internal Medicine, Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Anyang 14068, KoreaDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam 13620, KoreaDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam 13620, KoreaDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam 13620, KoreaDepartment of Radiology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam 13620, KoreaDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam 13620, KoreaBackground/Aim: This study investigated the predictive ability of intra-tumor enhancement on computed tomography (CT) for the outcomes of patients with pancreatic ductal adenocarcinoma (PDA). Methods: Multi-phase, contrast-enhanced CT (including unenhanced, pancreatic parenchymal phase (PPP) and portal venous phase (PVP)) images of patients diagnosed with non-metastatic PDA were analyzed to investigate prognostic factors. Results: Two hundred ninety-eight patients with PDA (159 with resectable pancreatic cancer (RPC) and 139 with borderline resectable pancreatic cancer (BRPC)/locally advanced pancreatic cancer (LAPC)) were included. The attenuation values of PDA during the PPP (94.5 vs. 60.7 HU; <i>p</i> <0.001) and PVP (101.5 vs. 75.5 HU; <i>p</i> <0.001) were higher in patients with RPC than in those with BRPC/LAPC. Well-enhanced PDA during the PPP was associated with longer overall survival in the RPC group (27.9 vs. 15.4 months; <i>p</i> <0.001) and the BRPC/LAPC group (22.7 vs. 13.6 months; <i>p</i> = 0.024). Patients with BRPC/LAPC who underwent neoadjuvant treatment and had well-enhanced PDA during the PPP were more likely to undergo resection. Although tumor size was also an independent prognostic factor, it was not correlated with intra-tumoral enhancement during the PPP. Conclusions: Intra-tumoral contrast enhancement on CT is an independent prognostic factor in patients with non-metastatic PDA.https://www.mdpi.com/2072-6694/14/10/2476radiologic prognostic factorcomputed tomographypancreatic cancer |
| spellingShingle | Dong Woo Shin Jaewon Park Jong-Chan Lee Jaihwan Kim Young Hoon Kim Jin-Hyeok Hwang Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma Cancers radiologic prognostic factor computed tomography pancreatic cancer |
| title | Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma |
| title_full | Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma |
| title_fullStr | Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma |
| title_full_unstemmed | Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma |
| title_short | Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma |
| title_sort | multi phase contrast enhanced computed tomography based radiomic prognostic marker of non metastatic pancreatic ductal adenocarcinoma |
| topic | radiologic prognostic factor computed tomography pancreatic cancer |
| url | https://www.mdpi.com/2072-6694/14/10/2476 |
| work_keys_str_mv | AT dongwooshin multiphasecontrastenhancedcomputedtomographybasedradiomicprognosticmarkerofnonmetastaticpancreaticductaladenocarcinoma AT jaewonpark multiphasecontrastenhancedcomputedtomographybasedradiomicprognosticmarkerofnonmetastaticpancreaticductaladenocarcinoma AT jongchanlee multiphasecontrastenhancedcomputedtomographybasedradiomicprognosticmarkerofnonmetastaticpancreaticductaladenocarcinoma AT jaihwankim multiphasecontrastenhancedcomputedtomographybasedradiomicprognosticmarkerofnonmetastaticpancreaticductaladenocarcinoma AT younghoonkim multiphasecontrastenhancedcomputedtomographybasedradiomicprognosticmarkerofnonmetastaticpancreaticductaladenocarcinoma AT jinhyeokhwang multiphasecontrastenhancedcomputedtomographybasedradiomicprognosticmarkerofnonmetastaticpancreaticductaladenocarcinoma |